MARKET

ECOL

ECOL

US Ecology
NASDAQ

Real-time Quotes | Nasdaq Last Sale

36.15
+0.22
+0.61%
After Hours: 36.15 0 0.00% 16:00 01/21 EST
OPEN
36.03
PREV CLOSE
35.93
HIGH
36.54
LOW
35.25
VOLUME
126.84K
TURNOVER
--
52 WEEK HIGH
55.79
52 WEEK LOW
24.94
MARKET CAP
1.14B
P/E (TTM)
-3.8209
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Should You Be Impressed By US Ecology's (NASDAQ:ECOL) Returns on Capital?
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. In a perfect...
Simply Wall St. · 3d ago
Heritage Environmental Services and Romeo Power Launch Commercial Fleet Electrification Program
Heritage Environmental Services, Inc. ("HES"), a leader in environmental and recycling services, and Romeo Power, Inc. ("Romeo Power") (NYSE: RMO), an energy technology leader delivering large-scale electrification solutions for complex commercial applicat...
Business Wire · 01/04 12:00
Heritage Environmental Services and Romeo Power Launch Commercial Fleet Electrification Program
Heritage Environmental Services, Inc. ("HES"), a leader in environmental and recycling services, and Romeo Power, Inc. ("Romeo Power") (NYSE: RMO), an energy technology leader delivering large-scale electrification solutions for complex commercial applicat...
BusinessWire · 01/04 09:00
NodThera Appoints Chief Medical Officer and Chief Financial Officer
NodThera, a biotechnology company developing a new class of medicines that inhibit the NLRP3 inflammasome to treat chronic inflammation, today announced the expansion of its senior leadership team with the appointments of Donald Johns, M.D., as Chief Medic...
BusinessWire · 12/15/2020 10:00
Is ECOL A Good Stock To Buy Now?
In this article we will analyze whether US Ecology Inc. (NASDAQ:ECOL) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense resources ...
Insider Monkey · 12/12/2020 03:00
A Look At US Ecology's (NASDAQ:ECOL) CEO Remuneration
This article will reflect on the compensation paid to Jeff Feeler who has served as CEO of US Ecology, Inc...
Simply Wall St. · 12/11/2020 05:45
Pandion Therapeutics Appoints Katina Dorton to its Board of Directors
Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced the appointment of Katina Dorton, J.D., M.B.A.,...
GlobeNewswire · 12/03/2020 13:00
Pandion Therapeutics Appoints Katina Dorton to its Board of Directors
WATERTOWN, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced the appointment of Katina Dorton, J.D., M.B.A., to Pandion’s board of directors and as chair of the audit committee. Ms. Dorton assumes the position of chair of the audit committee from Christopher Fuglesang, Ph.D., J.D., who will continue to serve as a member of the board and audit committee. Mitchell Mutz, Ph.D., resigned from the Company’s board on December 2, 2020. “Ms. Dorton brings to Pandion over two decades of financial expertise, leading a multitude of financial transactions for companies in the life sciences industry. We look forward to her contributions to the growth and value creation for Pandion as a newly public company,” said Rahul Kakkar, M.D., Chief Executive Officer of Pandion Therapeutics. “We also sincerely thank Mitchell for his guidance as we brought Pandion from an idea through its first-in-human clinical trial and wish him the best in his future endeavors.”“Pandion has the potential to bring about the next generation in autoimmune treatments with a unique focus on activating the body’s natural immune control nodes. I am excited to be a part of the team, particularly as we look to the Phase 1a results for the Company’s lead program, PT101, in early 2021,” commented Katina Dorton.Ms. Dorton currently serves on the board of directors for Fulcrum Therapeutics (Nasdaq: FULC) and US Ecology (Nasdaq: ECOL). She most recently served as Chief Financial Officer of Repare Therapeutics, a synthetic lethality and DNA repair-focused oncology company. Prior to Repare, Ms. Dorton served as Chief Financial Officer of AVROBIO, a lentiviral gene therapy company. Earlier in her career, she served as a managing director in investment banking for Morgan Stanley and Needham & Company and as an associate attorney at Sullivan & Cromwell. Ms. Dorton received her J.D. from the University of Virginia School of Law, her M.B.A. from George Washington University and her B.A. from Duke University.About Pandion Therapeutics Pandion Therapeutics is developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Pandion’s TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform enables the company to create a pipeline of product candidates using immunomodulatory effector modules, with the ability to also combine an effector module with a tissue-targeted tether module in a bifunctional format. Pandion’s lead product candidate PT101, a combination of an interleukin-2 mutein effector module with a protein backbone, is designed to selectively expand regulatory T cells systemically, without activating proinflammatory cells, such as conventional T cells and natural killer cells, is currently in a Phase 1a clinical trial. Pandion is continuing to develop and expand its library of effector and tether modules as part of its earlier-stage research and discovery pipeline. For more information, please visit www.pandiontx.com.Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding the Company’s strategy and clinical development plans, timelines and prospects, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with Pandion’s ability to obtain and maintain necessary approvals from the FDA and other regulatory authorities; initiate preclinical studies and clinical trials of PT101 and its other product candidates; advance PT101 and its other product candidates in preclinical research and clinical trials; replicate in clinical trials positive results found in preclinical studies; advance the development of its product candidates under the timelines it anticipates in current and future clinical trials; obtain, maintain or protect intellectual property rights related to its product candidates; manage expenses; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in the Company’s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof and should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.ContactsMedia: Kathryn Morris The Yates Network 914-204-6412 kathryn@theyatesnetwork.comInvestors: Michelle Avery Pandion Therapeutics 857-273-0444 investors@pandiontx.com
GlobeNewswire · 12/03/2020 13:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ECOL. Analyze the recent business situations of US Ecology through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ECOL stock price target is 40.00 with a high estimate of 44.00 and a low estimate of 36.00.
EPS
Institutional Holdings
Institutions: 302
Institutional Holdings: 28.85M
% Owned: 91.56%
Shares Outstanding: 31.51M
TypeInstitutionsShares
Increased
67
1.97M
New
37
-430.77K
Decreased
43
1.35M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Environmental Services & Equipment
-0.51%
Professional & Commercial Services
-0.92%
Key Executives
Chairman/President/Chief Executive Officer/Director
Jeffrey Feeler
Chief Financial Officer/Executive Vice President/Treasurer
Eric Gerratt
Chief Operating Officer/Executive Vice President
Simon Bell
Secretary
Wayne Ipsen
Executive Vice President/Director of Sales/Director of Marketing
Steven Welling
Executive Vice President
Andrew Marshall
Lead Director/Independent Director
Daniel Fox
Independent Director
Richard Burke
Independent Director
E. Renae Conley
Independent Director
Katina Dorton
Independent Director
Glenn Eisenberg
Independent Director
Ronald Keating
Independent Director
John Sahlberg
Independent Director
Melanie Steiner
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
01/02/2020
Dividend USD 0.18
01/16/2020
10/01/2019
Dividend USD 0.18
10/17/2019
07/01/2019
Dividend USD 0.18
07/18/2019
04/01/2019
Dividend USD 0.18
04/17/2019
01/02/2019
Dividend USD 0.18
01/17/2019
10/01/2018
Dividend USD 0.18
10/18/2018
07/02/2018
Dividend USD 0.18
07/19/2018
04/02/2018
Dividend USD 0.18
04/19/2018
01/02/2018
Dividend USD 0.18
01/18/2018
10/02/2017
Dividend USD 0.18
10/19/2017
07/03/2017
Dividend USD 0.18
07/19/2017
04/03/2017
Dividend USD 0.18
04/19/2017
01/03/2017
Dividend USD 0.18
01/18/2017
10/03/2016
Dividend USD 0.18
10/19/2016
07/01/2016
Dividend USD 0.18
07/20/2016
04/01/2016
Dividend USD 0.18
04/20/2016
01/04/2016
Dividend USD 0.18
01/20/2016
10/01/2015
Dividend USD 0.18
10/19/2015
07/01/2015
Dividend USD 0.18
07/17/2015
04/01/2015
Dividend USD 0.18
04/17/2015
01/07/2015
Dividend USD 0.18
01/21/2015
10/01/2014
Dividend USD 0.18
10/17/2014
07/01/2014
Dividend USD 0.18
07/17/2014
04/01/2014
Dividend USD 0.18
04/16/2014
01/02/2014
Dividend USD 0.18
01/15/2014
10/01/2013
Dividend USD 0.18
10/16/2013
07/01/2013
Dividend USD 0.18
07/15/2013
04/01/2013
Dividend USD 0.18
04/17/2013
12/12/2012
Dividend USD 0.18
12/18/2012
10/01/2012
Dividend USD 0.18
10/10/2012
07/02/2012
Dividend USD 0.18
07/11/2012
04/02/2012
Dividend USD 0.18
04/11/2012
01/03/2012
Dividend USD 0.18
01/11/2012
10/03/2011
Dividend USD 0.18
10/12/2011
07/01/2011
Dividend USD 0.18
07/13/2011
04/01/2011
Dividend USD 0.18
04/13/2011
01/03/2011
Dividend USD 0.18
01/12/2011
10/01/2010
Dividend USD 0.18
10/13/2010
07/01/2010
Dividend USD 0.18
07/14/2010
04/01/2010
Dividend USD 0.18
04/14/2010
01/04/2010
Dividend USD 0.18
01/13/2010
10/01/2009
Dividend USD 0.18
10/14/2009
07/01/2009
Dividend USD 0.18
07/15/2009
04/01/2009
Dividend USD 0.18
04/15/2009
01/05/2009
Dividend USD 0.18
01/14/2009
10/01/2008
Dividend USD 0.18
10/08/2008
07/01/2008
Dividend USD 0.18
07/09/2008
04/01/2008
Dividend USD 0.15
04/09/2008
01/02/2008
Dividend USD 0.15
01/09/2008
10/01/2007
Dividend USD 0.15
10/10/2007
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ECOL
US Ecology, Inc. is a provider of environmental services to commercial and government entities. The Company offers treatment, disposal and recycling of hazardous, non-hazardous and radioactive waste, as well as a range of field and industrial services. The Company operates in two business segments: Environmental Services, and Field & Industrial Services. Its Environmental Services segment provides a range of hazardous material management services, including transportation, recycling, treatment and disposal of hazardous and non-hazardous waste at Company-owned landfill, wastewater and other treatment facilities. The Company's Field & Industrial Services segment provides packaging and collection of hazardous waste and total waste management solutions at customer sites and through its transfer facilities. Its services include on-site management, waste characterization, transportation and disposal of non-hazardous and hazardous waste.
More

Webull offers kinds of US Ecology Inc stock information, including NASDAQ:ECOL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ECOL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ECOL stock methods without spending real money on the virtual paper trading platform.